Clinical Trial Update: Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update comparing low-dose azacitidine with pioglitazone and all-trans retinoic acid versus standard-dose azacitidine in patients aged 60 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• All-trans Retinoic Acid (all-trans retinoic acid)
• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: University Hospital Regensburg | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: TERMINATED